HRP20210373T1 - Multivalentno pneumokokno konjugirano cjepivo - Google Patents
Multivalentno pneumokokno konjugirano cjepivo Download PDFInfo
- Publication number
- HRP20210373T1 HRP20210373T1 HRP20210373TT HRP20210373T HRP20210373T1 HR P20210373 T1 HRP20210373 T1 HR P20210373T1 HR P20210373T T HRP20210373T T HR P20210373TT HR P20210373 T HRP20210373 T HR P20210373T HR P20210373 T1 HRP20210373 T1 HR P20210373T1
- Authority
- HR
- Croatia
- Prior art keywords
- serotypes
- formulation
- pneumococcal
- serotype
- pcv
- Prior art date
Links
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 title claims 12
- 150000004676 glycans Chemical class 0.000 claims 15
- 229920001282 polysaccharide Polymers 0.000 claims 15
- 239000005017 polysaccharide Substances 0.000 claims 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 8
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 229960002885 histidine Drugs 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 3
- 108010040473 pneumococcal surface protein A Proteins 0.000 claims 3
- 238000012371 Aseptic Filling Methods 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 238000011026 diafiltration Methods 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000011176 pooling Methods 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 238000004659 sterilization and disinfection Methods 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940124733 pneumococcal vaccine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Pripravak multivalentnog konjugiranog pneumokoknog cjepiva (PCV) koji se sastoji od:
a1) najmanje 12 kapsularnih polisaharida odabranih između serotipova 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F i 33F od S. pneumoniae aktiviranih CDAP-om i konjugiranim nosačem proteina odabranim između CRM197, pneumokoknog površinskog proteina A (PspA), pneumokoknog proteina adhezina (PsaA) ili njihove kombinacije, i izborno jednog ili više serotipova odabranih između 6C, 8, 10A, 11A, 12F, 15A, 23A, 23B i 35B od S. pneumoniae; ili
a2) najmanje 14 kapsularnih polisaharida odabranih između serotipova 1, 3, 4, 5, 6B, 7F, 9N, 9V, 14, 15B, 18C, 19A, 19F, 22F, 23F i 33F od S. pneumoniae aktiviranih CDAP-om i konjugiranih do CRM197, PspA, PsaA ili njihove kombinacije, i izborno jednog ili više serotipova odabranih između 6C, 8, 10A, 11A, 12F, 15A, 23A, 23B i 35B od S. pneumoniae; i
b) farmaceutski prihvatljivog nosača; i
izborno farmaceutski prihvatljivog razrjeđivača ili nosača; i
izborno sastojaka,
pri čemu pripravak sadrži kapsularne polisaharide serotipova 22F i 33F i ne sadrži kapsularne polisaharide serotipa 6A.
2. Pripravak prema zahtjevu 1, naznačen time što količina polisaharida iz svakog od serotipova iznosi 1 do 10 µg.
3. Pripravak prema zahtjevu 1, naznačen time što količina nosača proteina konjugiranog s polisaharidom iznosi 3 do 30 µg.
4. Pripravak prema zahtjevu 1, naznačen time što pojedinačna doza od 0,5 mL sadrži 2 µg svakog polisaharida; 30-40 µg CRM197 proteina nosača; 0,2 do 1 mg adjuvanta aluminij-fosfata; natrijev klorid i pufer.
5. Formulacija 14-valentnog sterilnog tekućeg pneumokoknog konjugiranog cjepiva (PCV) koja sadrži 2 µg svakog kapsularnog polisaharida serotipova 1, 3, 4, 5, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F i 33F, 4 µg serotipova 6B, svaki pojedinačno konjugiran na 32 µg CRM197; 0.125 mg elementarnog aluminij (0.5 mg aluminij-fosfata) adjuvanta; i pufer natrijevog klorida i L-histidina, pri čemu formulacija ne sadrži kapsularni polisaharid iz serotipa 6A.
6. Formulacija 13-valentnog sterilnog tekućeg pneumokoknog konjugiranog cjepiva (PCV) koja sadrži 2 µg svakog kapsularnog polisaharida serotipova 1, 3, 4, 5, 7F, 9V, 14, 18C, 19A, 19F, 22F i 33F, 4 µg serotipa 6B, svaki pojedinačno konjugiran na 32 µg CRM197; 0.125 mg elementarnog aluminij (0.5 mg aluminij-fosfata) adjuvanta; i pufer natrijevog klorida i L-histidina, pri čemu formulacija ne sadrži kapsularni polisaharid iz serotipa 6A.
7. Postupak za formuliranje 13-valentne PCV formulacije prema zahtjevu 6, sadrži korake:
a) konjugaciju pneumokoknih kapsularnih polisaharida poznate veličine iz serotipova 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F i 33F aktivirane pomoću CDAP-a, pojedinačno na imunogeni nosač proteina CRM197,
b) diafiltraciju pojedinačnih monovalentnih pneumokoknih konjugata, nakon čega slijedi pročišćavanje pomoću kromatografije isključivanja veličine,
c) analizu frakcija pomoću SEC-HPLC i udruživanje frakcija koje sadrže monovalentne pneumokokne konjugate prije sterilizacije filtra pomoću filtra od 0.2 µm,
d) formulaciju 13-valentnog PCV-a pomoću 13 monovalentnih pneumokoknih konjugata; 4.4 µg za serotip 6B; 2.2 µg za ostatak serotipova i adjuvant Adju-Phos® zajedno s odgovarajućim ekscipijentom uključujući natrijev klorid i pufer koji uključuje L-histidin, praćeno aseptičnim punjenjem,
naznačen time što navedena 13-valentna PCV formulacija ne sadrži kapsularni polisaharid iz serotipa 6A.
8. Postupak za formuliranje 14-valentne PCV formulacije prema zahtjevu 5 sadrži korake:
a) konjugaciju pneumokoknih kapsularnih polisaharida poznate veličine iz serotipova 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F i 33F aktiviranih pomoću CDAP-a, pojedinačno na imunogeni nosač proteina CRM197,
b) diafiltraciju pojedinačnih monovalentnih pneumokoknih konjugata, nakon čega slijedi pročišćavanje pomoću kromatografije isključivanja veličine,
c) analizu frakcija pomoću SEC-HPLC i udruživanje frakcija koje sadrže monovalentne pneumokokne konjugate prije sterilizacije filtra pomoću filtra od 0.2 µm i
d) formulaciju 14-valentnog PCV-a pomoću monovalentnih konjugata pneumokoka; 4.4 µg za serotip 6B; 2,2 µg za ostatak serotipova i adjuvant Adju-Phos®, zajedno s odgovarajućim ekscipijentom, uključujući natrijev klorid i pufer koji uključuje L-histidin, praćeno aseptičnim punjenjem,
naznačen time što navedena 14-valentna PCV formulacija ne sadrži kapsularni polisaharid iz serotipa 6A.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3140CH2015 | 2015-06-23 | ||
| PCT/IN2016/000157 WO2016207905A2 (en) | 2015-06-23 | 2016-06-21 | Multivalent pneumococcal conjugate vaccine |
| EP16753710.9A EP3313436B1 (en) | 2015-06-23 | 2016-06-21 | Multivalent pneumococcal conjugate vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210373T1 true HRP20210373T1 (hr) | 2021-04-30 |
Family
ID=56738144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210373TT HRP20210373T1 (hr) | 2015-06-23 | 2021-03-03 | Multivalentno pneumokokno konjugirano cjepivo |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11147863B2 (hr) |
| EP (1) | EP3313436B1 (hr) |
| JP (1) | JP6808658B2 (hr) |
| CN (1) | CN107810010A (hr) |
| AU (1) | AU2016285017B2 (hr) |
| BR (1) | BR112017028130A2 (hr) |
| CA (1) | CA2989230A1 (hr) |
| CY (1) | CY1123838T1 (hr) |
| DK (1) | DK3313436T3 (hr) |
| EA (1) | EA037373B1 (hr) |
| ES (1) | ES2857474T3 (hr) |
| HR (1) | HRP20210373T1 (hr) |
| HU (1) | HUE053272T2 (hr) |
| LT (1) | LT3313436T (hr) |
| MX (1) | MX2017016828A (hr) |
| PL (1) | PL3313436T3 (hr) |
| PT (1) | PT3313436T (hr) |
| RS (1) | RS61440B1 (hr) |
| SA (1) | SA517390539B1 (hr) |
| SI (1) | SI3313436T1 (hr) |
| WO (1) | WO2016207905A2 (hr) |
| ZA (1) | ZA201708713B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| RU2721128C2 (ru) * | 2015-07-21 | 2020-05-18 | Пфайзер Инк. | Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения |
| US11058757B2 (en) | 2016-03-31 | 2021-07-13 | Pogona, LLC | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| EP3518965A1 (en) | 2016-09-30 | 2019-08-07 | Biological E Limited | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| JP7186166B2 (ja) | 2016-12-30 | 2022-12-08 | バックスサイト・インコーポレイテッド | 非天然アミノ酸とのポリペプチド抗原接合体 |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| JP7132954B2 (ja) * | 2017-06-10 | 2022-09-07 | インベントプライズ リミテッド ライアビリティ カンパニー | 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン |
| CN108003240B (zh) * | 2017-12-04 | 2020-06-05 | 西安德轩驰生物科技有限公司 | 一种海水养殖鱼多联抗独特型卵黄抗体疫苗及其制备方法 |
| KR20230130153A (ko) | 2017-12-06 | 2023-09-11 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법 |
| AU2019215216A1 (en) | 2018-02-05 | 2020-07-23 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| BR112020021296A2 (pt) | 2018-04-18 | 2021-01-26 | Sk Bioscience Co., Ltd. | polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo |
| CN113194987A (zh) * | 2018-10-12 | 2021-07-30 | 生物E有限公司 | 多价肺炎球菌多糖-蛋白缀合的疫苗 |
| US20220296695A1 (en) | 2018-12-19 | 2022-09-22 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| ATE245446T1 (de) | 1992-02-11 | 2003-08-15 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
| DE69434079T2 (de) | 1993-03-05 | 2005-02-24 | Wyeth Holdings Corp. | Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin |
| AU678613B2 (en) | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| AU712981B2 (en) | 1995-03-22 | 1999-11-18 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
| FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| US8048432B2 (en) | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| TWI445545B (zh) | 2005-04-08 | 2014-07-21 | Wyeth Corp | 多價肺炎球菌多醣-蛋白質共軛物組合物 |
| US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP3470080A1 (en) * | 2005-12-22 | 2019-04-17 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| AU2007227504B2 (en) | 2006-03-17 | 2013-10-31 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for preparing complex multivalent immunogenic conjugates |
| CN101784282B (zh) * | 2007-06-26 | 2015-07-08 | 葛兰素史密丝克莱恩生物有限公司 | 包含肺炎链球菌荚膜多糖缀合物的疫苗 |
| CN101590224A (zh) | 2009-06-30 | 2009-12-02 | 广州精达医学科技有限公司 | 高效14价肺炎球菌结合疫苗 |
| TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| GB201003924D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CN103623401A (zh) | 2012-08-23 | 2014-03-12 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
| CN103656631B (zh) | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法 |
| CN103656632B (zh) | 2012-09-24 | 2016-01-13 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖组合物、其制备方法及应用 |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CN104069488A (zh) | 2013-03-29 | 2014-10-01 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
| US10280409B2 (en) | 2014-11-20 | 2019-05-07 | Biological E Limited | Codon optimized polynucleotide for high level expression of CRM197 |
-
2016
- 2016-06-21 PL PL16753710T patent/PL3313436T3/pl unknown
- 2016-06-21 US US15/772,771 patent/US11147863B2/en active Active
- 2016-06-21 WO PCT/IN2016/000157 patent/WO2016207905A2/en active Application Filing
- 2016-06-21 MX MX2017016828A patent/MX2017016828A/es unknown
- 2016-06-21 EP EP16753710.9A patent/EP3313436B1/en active Active
- 2016-06-21 SI SI201631120T patent/SI3313436T1/sl unknown
- 2016-06-21 BR BR112017028130A patent/BR112017028130A2/pt active Search and Examination
- 2016-06-21 ES ES16753710T patent/ES2857474T3/es active Active
- 2016-06-21 HU HUE16753710A patent/HUE053272T2/hu unknown
- 2016-06-21 CA CA2989230A patent/CA2989230A1/en active Pending
- 2016-06-21 RS RS20210164A patent/RS61440B1/sr unknown
- 2016-06-21 LT LTEP16753710.9T patent/LT3313436T/lt unknown
- 2016-06-21 JP JP2017566871A patent/JP6808658B2/ja active Active
- 2016-06-21 CN CN201680037079.2A patent/CN107810010A/zh active Pending
- 2016-06-21 DK DK16753710.9T patent/DK3313436T3/da active
- 2016-06-21 EA EA201890431A patent/EA037373B1/ru unknown
- 2016-06-21 PT PT167537109T patent/PT3313436T/pt unknown
- 2016-06-21 AU AU2016285017A patent/AU2016285017B2/en active Active
-
2017
- 2017-12-13 SA SA517390539A patent/SA517390539B1/ar unknown
- 2017-12-20 ZA ZA2017/08713A patent/ZA201708713B/en unknown
-
2021
- 2021-02-18 CY CY20211100136T patent/CY1123838T1/el unknown
- 2021-03-03 HR HRP20210373TT patent/HRP20210373T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3313436T (lt) | 2021-06-10 |
| WO2016207905A2 (en) | 2016-12-29 |
| EP3313436A2 (en) | 2018-05-02 |
| US20190240308A1 (en) | 2019-08-08 |
| WO2016207905A3 (en) | 2017-02-09 |
| PT3313436T (pt) | 2021-02-25 |
| US11147863B2 (en) | 2021-10-19 |
| DK3313436T3 (da) | 2021-03-08 |
| JP6808658B2 (ja) | 2021-01-06 |
| MX2017016828A (es) | 2018-09-18 |
| CA2989230A1 (en) | 2016-12-29 |
| SA517390539B1 (ar) | 2021-05-24 |
| PL3313436T3 (pl) | 2021-06-14 |
| CY1123838T1 (el) | 2022-05-27 |
| CN107810010A (zh) | 2018-03-16 |
| EA037373B1 (ru) | 2021-03-22 |
| EA201890431A1 (ru) | 2018-06-29 |
| AU2016285017A1 (en) | 2018-01-04 |
| JP2018518512A (ja) | 2018-07-12 |
| SI3313436T1 (sl) | 2021-09-30 |
| ZA201708713B (en) | 2019-08-28 |
| ES2857474T3 (es) | 2021-09-29 |
| RS61440B1 (sr) | 2021-03-31 |
| BR112017028130A2 (pt) | 2018-08-28 |
| HUE053272T2 (hu) | 2021-06-28 |
| EP3313436B1 (en) | 2020-12-23 |
| AU2016285017B2 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210373T1 (hr) | Multivalentno pneumokokno konjugirano cjepivo | |
| HRP20230416T1 (hr) | Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka | |
| HRP20120278T1 (hr) | Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom | |
| PH12020550891A1 (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
| AR116043A2 (es) | Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente | |
| NZ755770A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| CU24660B1 (es) | Composiciones de vacunas multivalentes que comprenden conjugados de polisacárido-proteína de streptococcus pneumoniae utilizando proteínas portadoras psaa y crm197 | |
| CO7461130A2 (es) | Composición multivalente de conjugados de proteína-polisacárido neumococico | |
| RU2018100123A (ru) | Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения | |
| NO20082647L (no) | Vaksine | |
| AR084158A1 (es) | Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas | |
| MX2009013949A (es) | Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae. | |
| PH12021551448A1 (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
| HRP20220573T1 (hr) | Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima | |
| BRPI0920460A2 (pt) | eixo de torcao com espessura de parede variavel longitudinalmente | |
| BR112015013560A2 (pt) | composição imunogênica multivalente; e composição farmacêutica para induzir uma resposta imunológica aos conjugados de polissacarídeo capsular de streptococcus pneumoniae | |
| BR112014032091A8 (pt) | Composição imunogênica multivalente, e composição farmacêutica para induzir uma resposta imune a um conjugado de polissacarídeo capsular de streptococcus pneumoniae | |
| BR112019001995A2 (pt) | composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína | |
| BR112022001654A2 (pt) | Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos | |
| TH128171A (th) | องค์ประกอบวัคซีนคอนจูเกต 15-วาเลนท์ นิวโมคอคคอล โพลีแซคคาไรด์-โปรตีน | |
| TH128171B (th) | องค์ประกอบวัคซีนคอนจูเกต 15-วาเลนท์ นิวโมคอคคอล โพลีแซคคาไรด์-โปรตีน |